ABBV34:BVMF
Abbvie Inc BDR
R$85.25
arrow_upward
+0.35%(+0.30) 1D
Oct 1, 3:04:51 PM GMT-3 · BRL
search
All symbols
No data
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ABBV34...
Open
R$83.25
High
R$85.25
Low
R$83.25
Mkt. cap
460.81B
Avg. vol.
1.16K
Volume
980.00
52-wk high
R$89.99
52-wk low
R$58.53
Shares outstanding
1.77B
No. of employees
57K
Open
R$83.25
High
R$85.25
Low
R$83.25
Mkt. cap
460.81B
Avg. vol.
1.16K
Volume
980.00
52-wk high
R$89.99
52-wk low
R$58.53
Shares outstanding
1.77B
No. of employees
57K
News stories
From web sources and news partners
Yahoo Finance Australia
·
1 hour ago
AbbVie (ABBV) Stock May Be 41% Undervalued Following JUVMO Approval
GuruFocus
·
2 hours ago
AbbVie's Rinvoq Shows Promise in Vitiligo Trials, ABBV Stock Hig
Kalkine Media
·
4 hours ago
Why Is AbbVie (NYSE:ABBV) Suddenly a Must-Watch Healthcare Stocks Stock Today?
Investing.com Canada
·
4 hours ago
AbbVie reports long-term vitiligo data for RINVOQ at EADV By Investing.com
Profile
AbbVie Inc., also known as AbbVie, is an American pharmaceutical company headquartered in North Chicago, Illinois. AbbVie produces drugs to treat a wide range of medical issues.
The company is ranked sixth on the list of largest biomedical companies by revenue. It is ranked 77th on the Fortune 500 and 108th on the Forbes Global 2000. The name "AbbVie" is derived from a combination of "Abbott", the name of its former parent company, with "vie", intended as a reference to a Latin root meaning 'life'. Wikipedia
About Abbvie Inc BDR
CEORobert A. Michael
Employees57K
FoundedApr 10, 2012
HeadquartersNorth Chicago, Illinois, United States
SectorBiotechnology
Websiteabbvie.com
Last report
Jul 31, 2026
Fiscal period
Q2 2026
EPS / Est. (USD)
$3.65 / $3.61
+1.08%beat
arrow_upward
Revenue / Est. (USD)
16.99B / 16.76B
+1.36%beat
arrow_upward
Fiscal Q2 2026 earnings call
youtube_liveWaiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
- Quarterly
- Annual
All values in USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
Revenue | 15.78B | 16.62B | 15.00B | 16.99B |
Cost of goods sold | 4.46B | 4.55B | 4.22B | 4.29B |
Cost of revenue | 4.46B | 4.55B | 4.22B | 4.29B |
Research and development expenses | 2.29B | 2.58B | 2.47B | 2.34B |
Total research and development expenses | - | - | - | - |
Selling, general, and admin expenses | 3.43B | 3.82B | 3.49B | 3.55B |
Operating expense | 5.72B | 6.40B | 5.96B | 5.90B |
Total operating expenses | 10.18B | 10.95B | 10.18B | 10.19B |
Operating income | 5.60B | 5.67B | 4.82B | 6.80B |
Other non operating income | 199.00M | 120.00M | -3.00M | -55.00M |
EBT including unusual items | 714.00M | 2.67B | 1.04B | 4.28B |
EBT excluding unusual items | 5.11B | 5.12B | 4.19B | 6.07B |
Income tax expense | 526.00M | 853.00M | 342.00M | 662.00M |
Effective tax rate | 73.67% | 31.97% | 32.92% | 15.47% |
Other operating expenses | - | - | - | - |
Net income | 186.00M | 1.82B | 695.00M | 3.61B |
Net profit margin | 1.18% | 10.93% | 4.63% | 21.27% |
Earnings per share | 1.86 | 2.71 | 2.65 | 3.65 |
Interest and investment income | 72.00M | 59.00M | 72.00M | 67.00M |
Interest expense | -739.00M | -714.00M | -717.00M | -746.00M |
Net interest expenses | -667.00M | -655.00M | -645.00M | -679.00M |
Depreciation and amortization charges | - | - | - | - |
EBITDA | 7.66B | 7.66B | 6.76B | 8.68B |
Gain or loss from assets sale | - | - | - | - |